PA-RELIEF-THERAPEUTICS
29.7.2020 07:32:11 CEST | Business Wire | Press release
RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.1
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com .
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial .”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.2 Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”3
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent4 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF (ISIN: CH0100191136).
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Youssef JG, Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide doi: 10.20944/preprints202007.0178.v1
2 Mason R. Pathogenesis of COVID-19 from a Cell Biologic Perspective. Eur Respir J. April 9 Epub ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/
4 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rising Global Bullion Market Risks Are Forcing European Investors to Rethink Physical Gold Access3.2.2026 10:35:00 CET | Press release
As volatility reshapes global financial markets, European institutional investors are turning to safe-haven assets. While physical gold remains one of the world's most resilient and attractive store-of-value assets, secure and verifiable access to bullion has become increasingly difficult. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203826775/en/ Illustrative image of physical gold bullion bars. (Photo: AETOSWire) Recent industry developments have placed structural pressure on the gold market. Elevated price levels have heightened concerns around counterfeit bars, fragmented supply chains, and the complexity of cross-border custody. For European institutions operating under strict regulatory oversight, the challenge is no longer whether to allocate to gold — but how to do so safely, transparently, and within established compliance frameworks. To this end, Golden Ark Reserve, operated by Golden Ark General Trading (FZC)
Hyper-Personalization at Scale: Why Brands Must Shift to an Agentic AI Strategy3.2.2026 10:00:00 CET | Press release
As Infobip celebrates 20 years of customer communication innovation, the AI-first company envisions the future of agentic AI Global AI-first cloud communications platform Infobip, celebrating two decades of innovation, predicts an imminent and seismic shift in brand-consumer engagement. Moving away from the current application-to-person (A2P) messaging, Infobip forecasts a widespread shift to an agent-to-person model, eventually leading to a fully autonomous agent-to-agent future by 2030. The Evolution of Engagement Swift AI adoption is driving enterprises toward agentic AI communication models, which drive autonomous customer communications across all touchpoints. This technology enables hyper-personalization across multiple channels, creating highly engaging content tailored to individual needs. Silvio Kutić, Infobip CEO, comments: “How we communicate with brands is constantly evolving. In this new agentic AI world, brands must seize the opportunity to take a holistic approach to com
Corona Cero Unveils Global Roster of Athlete Ambassadors to Champion TIME CERO at Milano Cortina 20263.2.2026 09:00:00 CET | Press release
A First-of-Its-Kind Initiative, In Partnership with International Olympics Committee (IOC), TIME CERO Empowers Athletes to Unwind, Recharge, and Celebrate the Moment Corona Cero Invites Fans to Celebrate Together in Italy with Corona Hotel, Casa Corona, and Other Immersive Activities Corona Cero today unveiled its global roster of brand ambassadors who will champion TIME CERO, the brand’s new initiative created in partnership with the IOC and Athlete365, throughout the Olympic Winter Games. Together, Team Corona Cero will bring the brand’s “For Every Golden Moment” global platform to life, reminding people that meaningful golden moments can happen anytime, anywhere, or in any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203205858/en/ Team Corona Cero Central to Corona Cero’s commitment as a Worldwide Olympic Partner, TIME CERO is designed to celebrate Olympians and help them relax, stay present, and embrace bala
Generali Deutschland AG Selects Clearwater Analytics to Modernize and Scale Investment Operations Unit-Linked Fund Business3.2.2026 09:00:00 CET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, announced today that Generali Deutschland AG has selected CWAN’s investment management platform for its €40 billion unit-linked fund (ULF) life insurance business, unifying processes across four subsidiaries and preparing the group for accelerated growth in one of Europe’s fastest-expanding sectors. The partnership reflects a strategic move ahead of unprecedented market expansion. The global unit-linked insurance market reached $906.9 billion in 2023 and is projected to grow at 10.9% annually through 2032, reaching $2.3 trillion, according to Allied Market Research. This growth trajectory is creating competitive separation between insurers capable of scaling operations and those constrained by fragmented systems across multiple European jurisdictions. Under a multi-year agreement, Generali Deutschland will consolidate portfolio management, order execution, and reconciliation on CWAN
Ares Completes Acquisition of BlueCove to Launch Systematic Credit Strategy3.2.2026 09:00:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it has completed its acquisition of all outstanding shares of BlueCove Limited (“BlueCove”), a London-based systematic fixed-income manager. The integrated BlueCove business will operate as Ares Systematic Credit, the latest strategy within the Ares Credit Group. Ares Systematic Credit offers systematic fixed-income strategies that harness the power of data and technology to deliver differentiated solutions to investors. The strategy leverages proprietary technology to support an evidence-based and data-driven investment process across high-yield, investment grade corporates, convertible bonds, and other liquid credit instruments in a variety of portfolio constructions. These methods seek to systematically access, select, analyze and deploy information to capitalize on market inefficiencies and generate high-quality alpha. Led by Alex Khein, most recently CEO of Blue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom